Achieving Durable Clinical Response with Targeted Treatment for Vitiligo

Author(s):

Raj Chovatiya, MD, PhD,Christopher G. Bunick, MD, PhD

In this MEDcast episode, Dr Chovatiya and Dr Bunick delve into the advancements in targeted treatments for vitiligo, exploring their potential to provide long-term efficacy and durable clinical response.

Now Viewing

EP: 1.Achieving Durable Clinical Response with Targeted Treatment for Vitiligo

0:53 Quality of life impact of vitiligo

2:55 Pathogenesis of vitiligo

5:08 Approaches to vitiligo treatment

8:30 Mechanism of JAK inhibitors

10:25 TRuE-V1 and TRuE-V2 studies for the JAK inhibitor ruxolitinib

14:15 Variation in repigmentation with vitiligo

17:20 Safety of topical ruxolitinib

21:00 Data from the long-term extension trial of ruxolitinib

25:75 Achieving meaningful treatment response in vitiligo

30:15 Investigational biomarkers and treatments for vitiligo